Provided are methods for treating inflammatory neurodegenerative diseases (e.g., multiple sclerosis, amyotrophic lateral sclerosis, Alzheimer's disease, Parkinson's disease, stroke/cerebral ischemia, head trauma, spinal cord injury, Huntington's disease, migraine, cerebral amyloid angiopathy, inflammatory neurodegenerative condition associated with AIDS, age-related cognitive decline； mild cognitive impairment and prion diseases in a mammal), or at least one symptom thereof in a subject by administering a therapeutic composition comprising at least one electrokinetically-altered fluids (e.g., electrokinetically-generated oxygen-enriched fluids) of the present invention. Particular aspects provide methods for inhibiting and/or modulating the function and/or activity of effector T-cells, and/or for cell-based tolerogenic therapy (e.g., by modulating development and/or function and/or activity of TREG cells and/or dendritic cells (DCs) and/or TH17 cells (e.g., ROR&gamma；t+ TH17 cells). In certain aspects such methods comprise ex vivo exposure of T-cells and/or APC (e.g., dendridic cells) to at least one electrokinetically-altered fluid as disclosed herein. Combination therapies are additionally provided.提供されるのは、対象の炎症性神経変性疾患、またはそれらの少なくとも１つの症状を、少なくとも１つの本発明の動電学的変性流体（例えば、動電学的生成酸素富化流体）を含む治療用組成物の投与により、治療する方法である。特定の態様は、エフェクターＴ細胞の機能および／または活性を抑制および／または調節するための、および／または細胞ベース寛容原性療法のための方法を提供する。特定の態様では、このような方法は、Ｔ細胞および／またはＡＰＣ（例えば、樹状細胞）を、少なくとも１つの本明細書で開示の動電学的変性流体にエクスビボで暴露することを含む。併用療法が、追加で提供される。【選択図】図２１Ｂ
